title: Is restoring platinum sensitivity the best goal for cetuximab in recurrent/metastatic nasopharyngeal cancer?
authors.forename: Lisa
authors.initials: L
authors.lastname: Licitra
authors.forename: Paolo
authors.initials: P
authors.lastname: Bossi
authors.forename: Laura D
authors.initials: LD
authors.lastname: Locati
authors.forename: Cristiana
authors.initials: C
authors.lastname: Bergamini
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D000068818:Cetuximab; D006801:Humans; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D009367:Neoplasm Staging; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D016190:Carboplatin; D000068818:Cetuximab